INTRODUCTION
============

Human bocavirus (HBoV) is a recently-discovered DNA virus of the Parvoviridae family. Since its first report in 2005, HBoV has been known to cause acute respiratory infections in children ([@B1][@B2][@B3][@B4][@B5][@B6]). The clinical manifestations of HBoV infection are diverse, ranging from a mild common cold to bronchopneumonia or asthma exacerbation and severe respiratory tract infection ([@B7]).

HBoV has been frequently co-detected with other respiratory viruses or respiratory pathogens in 40--75% of patients ([@B2][@B5][@B8]). This viral co-detection has started a debate about the role of HBoV as a true respiratory pathogen, but emerging evidence has supported the pathogenicity of HBoV. The presence of HBoV is rare in asymptomatic patients, and specifically, HBoV infections without other detected pathogens have been found in patients with respiratory tract symptoms. In addition, high viral loads have been associated with severe lower respiratory tract infections ([@B1][@B9][@B10]). In a recent prospective study, HBoV was the fourth most common pathogen in hospitalized children with respiratory tract diseases, with an incidence of 9.9% ([@B8]).

However, HBoV has been rarely detected in adults. According to a previous epidemiology study of respiratory viruses that have been detected in bronchoalveolar lavage (BAL), the incidence of HBoV infection was 3% followed by that of human metapneumovirus (4.2%) ([@B11]). Previous studies, mostly case reports ([@B12][@B13][@B14]), have shown that HBoV can cause severe pneumonia in immunocompromised adults or elderly patients; however, the clinical characteristics and burden of HBoV infection in adults have not been thoroughly elucidated.

As with other infections, chest computed tomography (CT) scans can show the pattern and extent of viral pneumonia, and CT findings of viral pneumonia tend to show similar patterns according to viral pathogen viridae, with partial overlap ([@B7][@B15]). However, for this approach, the CT findings of pneumonia need to be evaluated with respect to the etiology of each virus. To our knowledge, the CT findings of HBoV pneumonia have only been reported in one case report ([@B13]). Therefore, the purpose of this study was to describe the clinical characteristics of HBoV infections and the CT findings of HBoV pneumonia in adults using a large population cohort of a tertiary hospital.

MATERIALS AND METHODS
=====================

Data Collection
---------------

This retrospective cohort study was conducted with the approval of the Institutional Review Board at the Asan Medical Center (approval number: 2018-0009), and the requirement for informed consent was waived. A total of 185 patients who had laboratory-confirmed HBoV infection between January 2010 and December 2017 were identified by retrospective data search. Nasopharyngeal samples were collected when patients had symptoms of acute respiratory infection. BAL was performed if there was no definite pathogen identified from nasopharyngeal swab, even though pneumonia was suspected with abnormal chest radiography or CT findings. A reverse-transcription polymerase chain reaction assay was performed to detect respiratory viruses in nasopharyngeal secretions and or BAL fluid using a Seeplex® RV 15 ACE Detection kit or Anyplex™ II RV 16 Detection kit (Seegene Inc., Seoul, Korea). The laboratory threshold amplification product was 200 relative fluorescence units for detection of HBoV. Patient characteristics including demographics, smoking history, underlying chronic disease, body mass index, immune status, and features of HBoV infection, which included seasonality, type of infection (community acquired or nosocomial), and presence of co-infection were reviewed. We also studied laboratory findings and clinical outcomes which included emergency room visits, requirement for hospitalization, intensive care unit admission, and all-cause mortality rate (30 days, 90 days, and overall mortality from the initial diagnosis of HBoV infection).

Definitions
-----------

Upper respiratory infection (URI) was defined as positive HBoV in nasopharyngeal samples from patients with URI symptoms, such as cough, sputum, and rhinorrhea. Pneumonia was defined as the detection of HBoV in nasopharyngeal samples or BAL, with initial or new pulmonary opacities on chest radiography or CT images. Patients diagnosed with pneumonia two days after the initial URI diagnosis were considered to progress from URI to pneumonia. Immunocompromised patients were defined according to a previous study ([@B16]). Community-acquired infection was considered when patients developed acute respiratory symptoms while they were outside the hospital or within the first five days after admission ([@B17]). Co-infection was defined as the detection of other potential respiratory pathogens in nasopharyngeal samples, BAL, sputum, or blood cultures within 15 days before and after the HBoV infection. Neutropenia was defined as an absolute neutrophil count \< 1000/mL, and lymphopenia was defined as an absolute lymphocyte count \< 500/mL ([@B18]).

CT Acquisition
--------------

CT was performed in the patients with HBoV pneumonia with more severe clinical course. A total of 34 CT examinations obtained within 2 weeks after the diagnosis of HBoV pneumonia without co-infection were reviewed. CT examinations were performed on 16- or 64-detector CT scanners (SOMATOM Sensation 16, Siemens Healthcare, Forchheim, Germany; and LightSpeed VCT, GE Healthcare, Milwaukee, WI, USA). The 16-detector row CT used 120 kVp, 100 effective mAs with dose modulation, and a tube rotation time of 0.5 ms. The 64-detector row CT scanners were set to 120 kVp and 100 mAs to 400 mAs with dose modulation. All reconstructions were done at 2.5 mAs or 3 mm/5 mm thickness reconstruction intervals without a gap using the standard algorithm, and 1 mm or 1.25 mm thicknesses with 5 mm gaps using the high-frequency algorithm. Intravenous contrast agent was used in 17 of 34 patients. For enhanced chest CT, images were obtained after intravenous injection of 100 mL iopromide 300 (300 mg iodine/mL) (Ultravist®; Bayer AG, Berlin, Germany) at a rate of 2.5 mL/s by using a power injector.

Analysis of CT Findings
-----------------------

CT findings were reviewed in consensus by two chest radiologists (with 4 years of experience in chest imaging). Patterns of parenchymal abnormalities were assessed for the presence of consolidation, ground-glass opacity (GGO), centrilobular nodules, macronodules, cavities, and interlobular septal and/or intralobular interstitial thickening. In addition, the presence of lymphadenopathy (hilar/mediastinal), and pleural effusion was recorded. CT patterns were defined based on the glossary of terms provided by the Fleishner Society ([@B19]) and macronodules were defined as nodules more than 1.0 cm in diameter ([@B20]). With respect to the extent of parenchymal abnormalities, the total extent and the extent of each consolidation and GGO were assessed using a percent volumetric scale. The total number of involved lobes was also evaluated. The distribution of parenchymal abnormalities was evaluated for bilaterality and axial (central, peripheral, mixed), and longitudinal (upper, lower, mixed) locations. The inner two-thirds of the lung was defined as central and the outer third of the lung was defined as peripheral with respect to axial location. The lesions above the hilum were regarded as upper and those below the hilum were regarded as lower with respect to longitudinal distribution. The lesions that involved the lung parenchyma without dominant distribution were considered to have mixed distributions. Finally we divided the CT patterns of pneumonia into airway centric, multifocal pneumonia, focal pneumonia and diffuse pneumonia provided by Miller et al. ([@B21]). All axial and coronal CT images were reviewed on the picture archiving and communication system using lung (window width 1500 Hounsfield unit \[HU\], window level −700 HU) and mediastinal (window width 450 HU, window level 50 HU) windows for reading.

Statistical Analysis
--------------------

Clinical and CT findings of HBoV infections were compared for categorical variables using the chi-square test or Fisher\'s exact test and for continuous variables using the independent *t* test. Multivariable logistic regression was performed to identify cross-sectional associations between each risk factor and pneumonia occurrence among all patients. All variables with *p* values less than 0.1 in univariate analysis were entered into the multivariate analysis and the results were shown as odds ratios (ORs) and 95% confidence intervals (CIs). *P* values less than 0.05 were considered to be significant. All statistical calculations were performed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

Patient Characteristics and Seasonality of HBoV Infection
---------------------------------------------------------

A total of 185 patients were identified with laboratory-confirmed HBoV infection; 75 (40.5%) and 110 (59.5%) had URI alone and pneumonia, respectively. Patient characteristics are shown in [Table 1](#T1){ref-type="table"}. The mean age was 57 ± 19 years (range, 17--98 years), and 41.1% of the patients were over 65 years of age. Among the 185 patients, 76 (41.1%) patients were immunocompromised; 28 (36.8%) had solid tumors that were treated with chemotherapy within 6 months, since diagnosis of HBoV infection, 11 (14.5%) had hematologic malignancies, 19 (25.0%) had solid organ transplantations, and 18 (23.7%) received hematopoietic cell transplantation. One hundred nineteen (64.3%) patients had community-acquired infections, and co-infections were detected in 88 patients (47.6%) ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). The most frequent respiratory viral co-pathogens were rhinovirus (n = 8, 10.7%) in URI and adenovirus (n = 5, 4.6%) and influenza A or B virus (n = 5, 4.6%) in pneumonia. The monthly and year distributions of all patients with HBoV infections between January 2010 and December 2017 are shown in [Figure 1](#F1){ref-type="fig"}. HBoV infection was predominantly noted from February to June, with a peak incidence in April (15.7%) ([Fig. 1A](#F1){ref-type="fig"}). When the incidence of HBoV infections increased, pneumonia occurred more frequently, and this incidence has increased by approximately three times since 2014, compared to that before this period ([Fig. 1B](#F1){ref-type="fig"}).

Clinical Outcomes of HBoV Infection
-----------------------------------

Seventy-three patients (39.5%) visited the emergency department because of a HBoV infection. Among the 80 patients who visited the emergency department or the outpatient clinic, 46 patients (57.5%) were admitted to the hospital with secondary to infections. Seven patients (3.8%) required intensive care unit care with intubation. All-cause mortality rates at 30 and 90 days from diagnosis of HBoV infection were 7.6% and 13.0%, and the overall mortality rate was 21.1%. As for HBoV infection without co-infection, all-cause mortality rates at 30 and 90 days were 5.2% and 9.3% and the overall mortality rate was 20.6%.

Among the 83 patients who initially presented with URI, eight (9.6%) patients progressed from URI to pneumonia after a median of 3.5 days (range, 2--13 days). In a multivariable logistic regression among all patients, older age (OR, 1.02; CI, 1.00--1.04; *p* = 0.045) and nosocomial infection (OR, 2.07; CI, 1.05--4.10; *p* = 0.037) were significant factors associated with pneumonia ([Table 2](#T2){ref-type="table"}).

CT Findings of HBoV Pneumonia
-----------------------------

Among the 110 patients who had HBoV pneumonia, 56 had HBoV pneumonia without co-infection and CT findings were analyzed in 34 patients (immunocompetent: immunocompromised = 18:16) who performed chest CT within 2 weeks of HBoV detection ([Fig. 2](#F2){ref-type="fig"}). They had performed chest CT within an average 2.2 ± 3.6 days from the initial diagnosis.

The patterns and distributions of CT findings are described in [Table 3](#T3){ref-type="table"}. The most frequent CT findings were consolidation (n = 24, 70.6%) and GGO (n = 22, 64.7%) followed by interlobular and/or intralobular septal thickening (n = 14, 41.2%), bronchial wall thickening (n = 13, 38.2%), centrilobular nodules (n = 5, 14.7%) and macronodules (n = 3, 8.8%). Cavities were not observed in any patient. Mediastinal and/or hilar lymph node enlargement was found in 10 (29.4%) patients and pleural effusion was observed in 17 (50.0%) patients.

Parenchymal abnormalities were found bilaterally in 19 (55.9%) patients. The predominant axial distributions were mixed in 23 (67.6%) patients and peripheral in 9 (26.5%) patients. Predominant longitudinal locations were mixed in 18 (52.9%) patients followed by lower lung zone in 10 (29.4%) patients.

The average number of involved lobes and percent extent of the involved area of the lung were 3.4 ± 2.1 and 27.5 ± 25.2%, respectively. The most frequent pneumonia type was multifocal pneumonia (n = 12, 35.3%), followed by airway centric (n = 10, 29.4%), focal pneumonia (n = 8, 23.5%) and diffuse pneumonia (n = 4, 11.8%).

CT Findings according to Immune Status
--------------------------------------

The most frequent CT finding both in immunocompetent and immunocompromised patients was bilateral consolidation and/or GGO without axial and longitudinal zonal predominance. There was no significant difference in CT patterns and distributions between the two groups (all, *p* \> 0.05). Although the disease extent (total and each for consolidation and GGO) was larger in immunocompromised patients than in immunocompetent patients, differences were not statistically significant. The most frequent pneumonia type was airway centric for immunocompetent patients ([Fig. 3](#F3){ref-type="fig"}) and multifocal pneumonia for immunocompromised patients ([Fig. 4](#F4){ref-type="fig"}).

DISCUSSION
==========

In this study we showed that HBoV can cause respiratory infection in adults and older age and nosocomial infection were associated with HBoV pneumonia. The predominant CT findings of HBoV pneumonia were bilateral consolidation and/or GGO without zonal predominance with multifocal pneumonia pattern. The CT findings were not significantly different between immunocompetent and immunocompromised patients.

HBoV is a newly detected pathogen that can cause acute respiratory infection ([@B6]). Most studies have focused on HBoV infection in infants and young children ([@B2][@B4][@B8]), possibly due to its higher incidence in those populations than in adults ([@B12]). Moreover, most cases of HBoV infection in adults have been reported in immunocompromised patients ([@B1][@B12][@B13]). In this study, 58.9% of all patients with HBoV infection were immunocompetent showing that immunocompetent adults can also be infected with HBoV. We suspect that an increase in the frequency of prescription and technical improvements in viral detection tests, such as reverse-transcription polymerase chain reaction assays, may contribute to an increase in HBoV infection diagnoses.

In our study, 52.4% of patients showed HBoV infection without co-infection, which indicates that HBoV is a real etiological pathogen in adults. However, HBoV has also been frequently found with other respiratory pathogens, and the role of HBoV infection among co-pathogens has not been determined ([@B14]). Previous studies have demonstrated that high viral loads were significantly noted in patients with HBoV infection without co-infection, compared to patients with HBoV and co-pathogen infections, which suggests that high viral loads are indicative of a causative role for HBoV ([@B2][@B22][@B23]). Further studies are needed to determine whether HBoV among co-detected pathogens acts as a causative or exacerbating factor or whether our findings result from the long-term shedding of HBoV DNA.

An overall pneumonia rate of 59.5% was observed in this study. This is higher than that observed by previous studies, which reported a pneumonia rate of 29.2% in a pediatric cohort with HBoV infection ([@B14]) and a pneumonia rate of 25--49.2% in patients with human metapneumovirus ([@B17][@B24][@B25]).

Previously, one case report has described the CT findings of HBoV pneumonia as reticulonodular opacities predominantly in both lower lobes ([@B13]). Although HBoV pneumonia showed various CT features and it was difficult to describe specific findings, the HBoV pneumonia predominantly showed bilateral areas of consolidation (70.6%) and/or GGO (64.7%), whereas airway inflammatory findings such as bronchial wall thickening (38.2%) and centrilobular nodules (14.7%) were less frequently observed. When viral pneumonia is suggested in clinical practice, HBoV can be considered one of the etiologies, regardless of the patients\' immune status, particularly when chest CT reveals a multifocal pneumonia pattern.

However a multifocal pneumonia pattern can be also seen in other viral pneumonia conditions such as H1N1 influenza, Hanta and adenovirus infection with overlapping CT findings ([@B21][@B26][@B27]). H1N1 influenza frequently involves the peripheral and lower lung zones and pleural effusion is rare. Hantavirus may cause similar viral pneumonia in immunocompetent adults with respiratory distress with or without rapid progression to airspace consolidation. In addition, adenovirus can cause segmental consolidation and GGO in immunocompromised hosts.

CT findings of HBoV pneumonia did not significantly differ between patients who were immunocompetent and those who were immunocompromised. Although there was no statistical significance, the immunocompromised cohort showed a larger extent of total disease and consolidation than the immunocompetent group. Multifocal pneumonia pattern was more frequently found in immunocompromised patients than in immunocompetent patients. Similarly, a previous study about influenza viral pneumonia reported that the interstitial-parenchymal pattern (bilateral GGO and consolidation and/or interlobular septal thickening) was more frequently found in immunocompromised patients ([@B28]).

This study has several limitations. First, quantitative HBoV viral loads from patient respiratory secretions were not available in our study. Such measures can indicate disease severity as shown in a previous study, in which high viral load was a significant predictor of severe pneumonia in children ([@B22]). However, we did not routinely obtain viral loads for HBoV infection in our hospital. Second, we only evaluated CT finding of HBoV pneumonia without co-infection; therefore, the number of patients included for imaging analysis was small. However, this study involves the largest population of a rare incidence of HBoV pneumonia in adults. Last, not all patients with HBoV pneumonia underwent chest CT. Moreover, BAL procedure was not performed for all patients. Therefore, the incidence of mild pneumonia, which can be detected on CT scan or BAL, may be underestimated.

In conclusion, HBoV infection can cause respiratory infection in adults and is associated with a high incidence of pneumonia, especially in older patients and patients with nosocomial infection. The HBoV pneumonia can be included as one of the differential diagnosis in adult patients, whether immunocompromised or immunocompetent, especially when multifocal areas of consolidation and/or GGO are seen on chest CT. Early CT diagnosis may allow timely initiation of effective treatment.
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###### Supplementary Table 1

Identified Respiratory Pathogens in Patients with Human Bocavirus Pneumonia

![Monthly and yearly distributions of HBoV infections from January 2010 and December 2017.\
Number of patients with HBoV infections among 185 patients are shown by month **(A)** and by year **(B)** according to respiratory site and presence of co-pathogens. HBoV = human bocavirus, URI = upper respiratory infection](kjr-20-1226-g001){#F1}

![Flow diagram of patient selection with HBoV infection.](kjr-20-1226-g002){#F2}

![30-year-old female without underlying disease was admitted with cough and fever.\
**A, B.** CT showed multiple ill-defined centrilobular nodules with bronchial wall thickening (airway centric pattern) in both lungs. Three days later, lesions had resolved completely (not shown).](kjr-20-1226-g003){#F3}

![53-year-old male who had undergone liver transplantation eight months earlier presented with fever at emergency department.\
**A, B.** Bilateral ground glass opacities and peribronchial consolidations (multifocal pneumonia pattern) without pleural effusion were shown on CT images. He was admitted to intensive care unit, and intubated (not shown). Three weeks after initial presentation, HBoV pneumonia was improved, and patient was discharged uneventfully.](kjr-20-1226-g004){#F4}

###### Patient Characteristics and Clinical Outcomes of HBoV Infection

![](kjr-20-1226-i001)

  Characteristics                        Total (n = 185)   URI (n = 75)   Pneumonia (n = 110)   *P*
  -------------------------------------- ----------------- -------------- --------------------- -------
  Age                                    57 ± 19           53 ± 19        59 ± 18               0.033
  Male                                   115 (62.2)        41 (54.7)      74 (67.3)             0.083
  Smoking                                                                                       0.132
   Never smoker                          120 (64.9)        48 (64.0)      72 (65.5)             
   Former smoker                         24 (20.5)         16 (21.3)      22 (20.0)             
   Current smoker                        24 (13.0)         9 (12.0)       15 (13.6)             
  Chronic disease                        72 (38.9)         26 (34.7)      46 (41.8)             0.959
   DM                                    43 (23.2)         14 (18.7)      29 (26.4)             
   COPD                                  16 (8.6)          4 (5.3)        12 (10.9)             
   CKD                                   5 (2.7)           3 (4.0)        2 (1.8)               
   Others                                21 (11.4)         8 (10.7)       13 (11.8)             
  Immune status                                                                                 0.805
   Immunocompetent                       109 (58.9)        45 (60.0)      64 (58.2)             
   Immunocompromised                     76 (41.1)         30 (40.0)      46 (41.8)             
  Body mass index, kg/m^2^               22.6 ± 4.3        23.2 ± 3.5     22.2 ± 4.8            0.130
  Type of infection                                                                             0.035
   Community-acquired                    119 (64.3)        55 (73.3)      64 (58.2)             
   Nosocomial                            66 (35.7)         20 (26.7)      46 (41.8)             
  Co-infection                                                                                  0.615
   None                                  97 (52.4)         41 (54.7)      56 (50.9)             
   Yes                                   88 (47.6)         34 (45.3)      54 (49.1)             
  Emergency room visit                   73 (39.5)         28 (37.3)      45 (40.9)             0.239
  Admission secondary to infection^\*^   46/80 (57.5)      12/34 (35.3)   34/46 (73.9)          0.001
  ICU admission                          7 (3.8)           2 (2.7)        5 (4.5)               0.703
  All-cause mortality, 30 d^†^           14 (7.6)          4 (5.3)        10 (9.1)              0.343
  All-cause mortality, 90 d^†^           24 (13.0)         6 (8.0)        18 (16.4)             0.096
  Overall mortality^†^                   39 (21.1)         10 (13.3)      29 (26.4)             0.033
  Neutrophil count                                                                              1.000
   \> 1.0×10^3^/μL                       171 (93.4)        69 (92.0)      102 (92.7)            
   ≤ 1.0×10^3^/μL                        12 (6.6)          5 (6.7)        7 (6.4)               
  Lymphocyte count                                                                              0.084
   \> 0.5×10^3^/μL                       147 (92.4)        64 (86.5)      83 (76.1)             
   ≤ 0.5 × 10^3^/μL                      36 (9.7)          10 (13.5)      26 (23.9)             
  Steroid use                                                                                   0.878
   None                                  142 (76.8)        58 (77.3)      84 (76.4)             
   Yes                                   43 (23.2)         17 (22.7)      26 (23.6)             

Data are indicated as number and percentages in parenthesis or means ± standard deviation unless specified otherwise. ^\*^This analysis was restricted to outpatients or patients who visited emergency room, ^†^Specific mortality rates at 30 days, 90 days and overall for HBoV infection without co-infection were 5.2%, 9.3%, and 20.6%, respectively. CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, d = day, DM = diabetes mellitus, HBoV = human bocavirus, ICU = intensive care unit, URI = upper respiratory infection

###### Clinical Factors Associated with HBoV Pneumonia

![](kjr-20-1226-i002)

  Characteristics              Univariate Analysis   Multivariate Analysis                               
  ---------------------------- --------------------- ----------------------- ------- ------ ------------ -------
  Age                          1.02                  1.00--1.03              0.034   1.02   1.00--1.04   0.045
  Sex                                                                                                    
   Male                        1.00                                                  1.00                
   Female                      0.59                  0.32--1.07              0.084   0.57   0.30--1.09   0.090
  Smoking                                                                                                
   Never smoker                1.00                                                                      
   Former/current smoker       0.99                  0.53--1.84              0.966                       
  Underlying chronic disease                                                                             
   No                          1.00                                                                      
   Yes                         1.36                  0.74--2.49              0.333                       
  Neutropenia                                                                                            
   No                          1.00                                                                      
   Yes                         0.95                  0.29--3.11              0.928                       
  Lymphopenia                                                                                            
   No                          1.00                                                  1.00                
   Yes                         2.01                  0.90--4.46              0.099   1.80   0.78--4.14   0.170
  Type of infection                                                                                      
   Community-acquired          1.00                                                  1.00                
   Nosocomial                  1.98                  1.05--3.74              0.044   2.07   1.05--4.10   0.037
  Steroids                                                                                               
   None                        1.00                                                                      
   Yes                         1.06                  0.53--2.10              0.888                       
  Co-infection                                                                                           
   None                        1.00                                                                      
   Yes                         1.16                  0.65--2.10              0.622                       
  Body mass index, kg/m^2^     0.94                  0.87--1.02              0.142                       

CI = confidence interval, OR = odds ratio

###### CT Findings of HBoV Pneumonia without Co-Infection according to Immune Status

![](kjr-20-1226-i003)

  CT Findings                                       Total (n = 34)   Immunocompetent (n = 18)   Immunocompromised (n = 16)   *P*
  ------------------------------------------------- ---------------- -------------------------- ---------------------------- -------
  Consolidation                                     24 (70.6)        12 (66.7)                  12 (75.0)                    0.715
  GGO                                               22 (64.7)        11 (61.1)                  11 (68.8)                    0.642
  Centrilobular nodules                             5 (14.7)         3 (16.7)                   2 (12.5)                     1.000
  Macronodules (\> 1.0 cm)                          3 (8.8)          1 (5.6)                    2 (12.5)                     0.591
  Interlobular and intralobular septal thickening   14 (41.2)        8 (44.4)                   6 (37.5)                     0.681
  Bronchial wall thickening                         13 (38.2)        8 (44.4)                   5 (31.3)                     0.429
  Lymphadenopathy                                   10 (29.4)        7 (38.9)                   3 (18.8)                     0.270
   Hilar                                            5                3                          2                            
   Mediastinal                                      1                1                          0                            
   Hilar and mediastinal                            4                3                          1                            
  Pleural effusion                                  17 (50.0)        7 (38.9)                   10 (62.5)                    0.169
  No. of involved lobes                             3.4 ± 2.1        3.3 ± 2.0                  3.4 ± 2.2                    0.886
  Total extent of involved lobes (%)                27.5 ± 25.2      21.7 ± 22.6                34.0 ± 27.0                  0.157
  Consolidation extent (%)                          13.4 ± 15.9      10.6 ± 13.4                16.6 ± 18.2                  0.273
  GGO extent (%)                                    10.3 ± 17.7      10.3 ± 19.6                10.4 ± 15.9                  0.988
  Bilaterality                                      19 (55.9)        11 (61.1)                  8 (50.0)                     0.515
  Axial location                                                                                                             0.360
   Central                                          2 (5.9)          2 (11.1)                   0 (0.0)                      
   Peripheral                                       9 (26.5)         5 (27.8)                   4 (25.0)                     
   Mixed                                            23 (67.6)        11 (61.1)                  12 (75.0)                    
  Longitudinal location                                                                                                      0.759
   Upper                                            6 (17.6)         4 (22.2)                   2 (12.5)                     
   Lower                                            10 (29.4)        5 (27.8)                   5 (31.3)                     
   Mixed                                            18 (52.9)        9 (50.0)                   9 (56.3)                     
  Pneumonia type                                                                                                             0.275
   Airway centric                                   10 (29.4)        8 (44.4)                   2 (12.5)                     
   Multifocal pneumonia                             12 (35.3)        4 (22.2)                   8 (50.0)                     
   Focal pneumonia                                  8 (23.5)         4 (22.2)                   4 (25.0)                     
   Diffuse pneumonia                                4 (11.8)         2 (11.1)                   2 (12.5)                     

Data demonstrated mean ± standard deviation or number and percentages in parenthesis. GGO = ground-glass opacity
